高盛相信，信达生物将继续保持其在中国生物技术领域的领先地位，主要得益于拥有大量针对下一代免 疫肿瘤靶点的新型分子，并已获得令人鼓舞的初步数据(如IBI363(PD-1/IL-2α偏向性双特异性抗体)，在 免疫治疗/冷肿瘤中具有差异化的药物特性；强大的商业化能力及与全球合作伙伴，特别是礼来公司的 深度合作等。 高盛发布研报称，信达生物(01801)昨日(8日)宣布与礼来(LLY.US)美元的里程碑付款；及基于中国以外 地区净销售额的分级销售特许权使用费。高盛考虑到当前市场隐含的加权平均资本成本(12%)较高，认 为其目前股价被低估；予该股"买入"评级；基于风险调整后、现金流量折现法，予目标价102.85港元。 信达生物 分时图 日K线 周K线 月K线 85.40 5.90 7.42% 8.18% 5.45% 2.73% 0.00% 2.73% 5.45% 8.18% 73.00 75.17 77.33 79.50 81.67 83.83 86.00 09:30 10:30 12:00/13:00 14:00 16:10 0 31万 62万 94万 ...

Core Viewpoint - Eli Lilly (LLY.US) has announced a definitive acquisition agreement with Orna Therapeutics to enhance its position in cell therapy and gene medicine, with a potential total payout of up to $2.4 billion to Orna's shareholders [1]. Group 1: Acquisition Details - The acquisition includes a cash payment to Orna's shareholders, which consists of an upfront payment and additional payments contingent upon achieving specific clinical development milestones [1]. - The primary assets being acquired are Orna's circular RNA technology platform and its in vivo CAR-T pipeline, which are expected to strengthen Eli Lilly's capabilities in innovative therapies [1]. Group 2: Technology and Innovation - Orna Therapeutics specializes in engineering circular RNA combined with novel lipid nanoparticle (LNP) delivery systems, allowing patients' bodies to generate therapeutic cells that target the root causes of diseases [1]. - The technology offers advantages such as prolonged expression of therapeutic proteins, addressing limitations currently faced by RNA and cell therapies [1]. Group 3: Key Projects - Orna's flagship project, ORN-252, is a clinical-stage in vivo CAR-T therapy targeting CD19, primarily aimed at treating B-cell mediated autoimmune diseases, which aligns with Eli Lilly's strategic focus [1].

Core Viewpoint - Eli Lilly (LLY.US) has announced a definitive acquisition agreement with Orna Therapeutics to enhance its position in cell therapy and gene drug sectors, with a potential total payout of up to $2.4 billion to Orna's shareholders [1] Group 1: Acquisition Details - Eli Lilly's acquisition of Orna includes a cash payment to shareholders, which may reach up to $2.4 billion, consisting of upfront payments and milestone payments tied to specific clinical development achievements [1] - The acquisition focuses on Orna's circular RNA technology platform and in vivo CAR-T pipeline, which are expected to strengthen Eli Lilly's capabilities in innovative therapies [1] Group 2: Technology and Innovation - Orna specializes in engineering circular RNA combined with novel lipid nanoparticle (LNP) delivery systems, allowing patients' bodies to generate therapeutic cells that target the root causes of diseases [1] - The technology offers advantages such as prolonged expression of therapeutic proteins, addressing limitations in current RNA and cell therapies [1] Group 3: Key Projects - Orna's core project, ORN-252, is a clinically ready in vivo CAR-T therapy targeting CD19, primarily aimed at treating B cell-mediated autoimmune diseases, which aligns with Eli Lilly's strategic focus [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed drug, GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - GenSci136 is a class 1 therapeutic biological product designed to treat IgAN, showcasing the company's commitment to innovative drug development [1] - The drug is a B-cell maturation antigen (BCMA) trimeric fusion protein, which utilizes novel molecular design to enhance the blocking activity against endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells [1] - GenSci136 is expected to provide a new, safe, and effective first-line targeted treatment option for IgAN patients, significantly improving their long-term prognosis [1] Group 2 - The design of GenSci136 includes an anti-human serum albumin heavy chain single-domain antibody to extend its half-life in the body, suggesting a potential for efficient and sustained therapeutic effects [1] - The drug aims to address various autoimmune diseases caused by pathogenic antibodies, indicating its broader therapeutic potential beyond IgAN [1] - The approval of the clinical trial marks a significant milestone for the company, reflecting its ongoing efforts in advancing biopharmaceutical innovations [1]

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

Group 1 - The core point of the article is that Shanghai Laishi (002252) reported a total of 115,163 shareholders as of January 30, 2026 [1]

Core Viewpoint - The company is advancing its clinical research with a focus on innovative therapies for bladder cancer and EBV-related malignancies [2] Group 1: Product Development - The company is in Phase III clinical trials for a therapeutic Bacillus Calmette-Guérin (BCG) vaccine aimed at treating non-muscle invasive bladder cancer and preventing recurrence after transurethral resection of Ta or T1 stage bladder papilloma [2] - The company is also conducting preclinical research on an EBV vaccine intended to prevent malignancies associated with Epstein-Barr virus [2] - Ongoing product development updates will be disclosed through the company's information channels [2]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership aimed at advancing innovative drugs in oncology and immunology, with Innovent leading the development and retaining rights in Greater China while Eli Lilly secures global rights outside this region [1][2]. Group 1: Financial Aspects - Innovent will receive an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [1]. - Following the announcement, Innovent's stock price surged by 7.42%, closing at HKD 85.40 per share, with a market capitalization of HKD 148.2 billion [2]. Group 2: Strategic Importance - The collaboration is characterized as a pure incremental partnership, focusing on new targets and molecules outside Innovent's existing clinical pipeline [2]. - Innovent's management highlighted the recognition of its R&D capabilities globally and the long-standing relationship with Eli Lilly as key factors for this partnership [2]. Group 3: Historical Context - Previous collaborations between Innovent and Eli Lilly include the development of the PD-1 inhibitor, which became a cornerstone product for Innovent after its launch in 2018 [3]. - Innovent has also introduced the GLP-1 dual receptor agonist from Eli Lilly, which is set to launch in 2025, marking a significant addition to its product portfolio [3]. Group 4: Market Position and Future Plans - Innovent is seen as a leading player in the domestic innovative drug sector, having capitalized on significant targets like PD-1 and GLP-1, which are closely associated with Eli Lilly [2][3]. - The company aims to enter a new phase of dual-driven product lines and internationalization by 2025, with plans to establish a global R&D and commercialization platform [8][9]. - Innovent's goal includes having five pipelines enter global multi-center Phase III clinical trials by 2030, with a revenue target of CNY 20 billion by 2027 [9].

Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange after withdrawing its IPO application from the Beijing Stock Exchange, reflecting a strategic shift for unprofitable biotech companies in the current market environment [1][3][6] Company Overview - Puxi Pharmaceutical, established in 2016, focuses on the field of immune inflammation, with its core product being Pumeixin (PG-011) [3][6] - The company has not yet launched any products, with its core product currently in various stages of clinical trials [1][3] Financial Performance - The company reported a cumulative loss exceeding 300 million yuan from 2024 to the first three quarters of 2025, with a net loss of 178.496 million yuan for 2024 and 125 million yuan for the first three quarters of 2025 [2][6] - Puxi Pharmaceutical's revenue was zero for 2022 and 2023, with only 47,200 yuan in revenue from other business activities in 2024 [5][6] Strategic Shift - The decision to switch from the Beijing Stock Exchange to the Hong Kong Stock Exchange is seen as a pragmatic adjustment due to the more stringent review process for unprofitable companies on the former [1][6] - The Hong Kong Stock Exchange's Chapter 18A is designed for unprofitable biotech companies, offering lower listing thresholds and faster access to capital [1][6] Product Development - Pumeixin has two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trial stages [7][8] - The gel has completed Phase III trials for adults and adolescents, while the nasal spray is in Phase III trials for adults [7] Commercial Collaboration - Puxi Pharmaceutical has signed an exclusive commercialization agreement with Jichuan Pharmaceutical, allowing the latter to market Pumeixin nasal spray in China for up to 1 billion yuan [8][9] - This partnership is expected to provide essential funding and leverage Jichuan's commercial expertise to expedite market entry for Puxi's products [9]

Core Viewpoint - As of January 30, 2026, the number of common stock shareholders for Zhifei Biological Products Co., Ltd. (stock code: 300122) is reported to be 128,281 [1] Company Summary - Zhifei Biological Products Co., Ltd. has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [1]